TNX-4700
Preclinical
Phase I
Phase II
Phase III
Immuno-oncology Indications
Preclinical
Preclinical
Tonix is developing TNX-4700, a human anti-BTLA monoclonal antibody (mAB) for immuno-oncology indications. The mAb technology was licensed from Curia.
BTLA (B and T lymphocyte attenuator) is a protein on the surface of tumor infiltrating lymphocytes. Targeting BTLA is a promising target in immuno-oncology since its ligand HVEM is expressed and/or upregulated in the tumor microenvironment of many cancers including melanoma, non-small cell lung cancer, colorectal cancer, gastric cancer, glioblastoma, and prostate cancer and generally correlates with reduced overall survival.
TNX-4700 is an investigational new biologic and has not been approved for any indication.